Literature DB >> 24682990

Nontraditional therapies to treat Helicobacter pylori infection.

Morris O Makobongo1, Jeremy J Gilbreath, D Scott Merrell.   

Abstract

The Gram-negative pathogen Helicobacter pylori is increasingly more resistant to the three major antibiotics (metronidazole, clarithromycin and amoxicillin) that are most commonly used to treat infection. As a result, there is an increased rate of treatment failure; this translates into an overall higher cost of treatment due to the need for increased length of treatment and/or the requirement for combination or sequential therapy. Given the rise in antibiotic resistance, the complicated treatment regime, and issues related to patient compliance that stem from the duration and complexity of treatment, there is clearly a pressing need for the development of novel therapeutic strategies to combat H. pylori infection. As such, researchers are actively investigating the utility of antimicrobial peptides, small molecule inhibitors and naturopathic therapies. Herein we review and discuss each of these novel approaches as a means to target this important gastric pathogen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682990     DOI: 10.1007/s12275-014-3603-5

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  172 in total

1.  Optimization of Allium sativum solvent extraction for the inhibition of in vitro growth of Helicobacter pylori.

Authors:  Pablo Cañizares; Ignacio Gracia; Luis A Gómez; Carlos Martín de Argila; Luis de Rafael; Antonio García
Journal:  Biotechnol Prog       Date:  2002 Nov-Dec

2.  Flavonoids with anti-Helicobacter pylori activity from Cistus laurifolius leaves.

Authors:  Osman Ustün; Berrin Ozçelik; Yakut Akyön; Ufuk Abbasoglu; Erdem Yesilada
Journal:  J Ethnopharmacol       Date:  2006-06-18       Impact factor: 4.360

3.  Evaluation of antiulcer activity of chromanone fraction from Calophyllum brasiliesnse Camb.

Authors:  Larissa Maria Scalon Lemos; Thaís Bezerra Martins; Guilherme Henrique Tanajura; Vanessa Fátima Gazoni; Josiane Bonaldo; Claudia Léia Strada; Marcos Gabriel da Silva; Evandro Luiz Dall'oglio; Paulo Teixeira de Sousa Júnior; Domingos Tabajara de Oliveira Martins
Journal:  J Ethnopharmacol       Date:  2012-03-15       Impact factor: 4.360

4.  Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori.

Authors:  Byeoung-Soo Park; Hyun-Kyung Lee; Sung-Eun Lee; Xiang-Lan Piao; Gary R Takeoka; Rosalind Y Wong; Young-Joon Ahn; Jeong-Han Kim
Journal:  J Ethnopharmacol       Date:  2005-12-15       Impact factor: 4.360

5.  Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues.

Authors:  K Kawauchi; A Yagihashi; N Tsuji; N Uehara; D Furuya; D Kobayashi; N Watanabe
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

6.  Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori.

Authors:  Dae-Sung Kim; Moo-Song Lee; Young-Sik Kim; Dong-Hyun Kim; Jong-Myon Bae; Myung-Hee Shin; Yoon-Ok Ahn
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

7.  Essential oils as components of a diet-based approach to management of Helicobacter infection.

Authors:  G E Bergonzelli; D Donnicola; N Porta; I E Corthésy-Theulaz
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Allyl-thiosulfinates, the bacteriostatic compounds of garlic against Helicobacter pylori.

Authors:  Pablo Cañizares; Ignacio Gracia; Luis A Gómez; Carlos Martín de Argila; Daniel Boixeda; Antonio García; Luis de Rafael
Journal:  Biotechnol Prog       Date:  2004 Jan-Feb

9.  Investigations into the antibacterial activities of phytotherapeutics against Helicobacter pylori and Campylobacter jejuni.

Authors:  C Cwikla; K Schmidt; A Matthias; K M Bone; R Lehmann; E Tiralongo
Journal:  Phytother Res       Date:  2010-05       Impact factor: 5.878

10.  Factors associated with treatment failure of Helicobacter pylori infection in a developing country.

Authors:  Dulciene Maria Magalhães Queiroz; Renato Dani; Luciana Diniz Silva; Adriana Santos; Liano Sia Moreira; Gifone Aguiar Rocha; Paulo Renato Valle Corrêa; Luiz Fernando Abrahão Reis; Ana Margarida Ferreira Nogueira; Mônica Maria Demas Alvares Cabral; Ana Maria Brás Esteves; Jansen Tanure
Journal:  J Clin Gastroenterol       Date:  2002-10       Impact factor: 3.062

View more
  11 in total

1.  Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides.

Authors:  Menghua Xiong; Yan Bao; Xin Xu; Hua Wang; Zhiyuan Han; Zhiyu Wang; Yeqing Liu; Songyin Huang; Ziyuan Song; Jinjing Chen; Richard M Peek; Lichen Yin; Lin-Feng Chen; Jianjun Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-13       Impact factor: 11.205

2.  Helicobacter pylori outer membrane protein, HomC, shows geographic dependent polymorphism that is influenced by the Bab family.

Authors:  Aeryun Kim; Stephanie L Servetas; Jieun Kang; Jinmoon Kim; Sungil Jang; Yun Hui Choi; Hanfu Su; Yeong-Eui Jeon; Youngmin A Hong; Yun-Jung Yoo; D Scott Merrell; Jeong-Heon Cha
Journal:  J Microbiol       Date:  2016-11-26       Impact factor: 3.422

3.  Morphological changes in human gastric epithelial cells induced by nuclear targeting of Helicobacter pylori urease subunit A.

Authors:  Jung Hwa Lee; So Hyun Jun; Jung-Min Kim; Seung Chul Baik; Je Chul Lee
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

Review 4.  Dietary amelioration of Helicobacter infection.

Authors:  Jed W Fahey; Katherine K Stephenson; Alison J Wallace
Journal:  Nutr Res       Date:  2015-03-06       Impact factor: 3.315

Review 5.  A Comprehensive Study on the Antimicrobial Properties of Resveratrol as an Alternative Therapy.

Authors:  Ehsan Abedini; Ehsaneh Khodadadi; Elham Zeinalzadeh; Seyyed Reza Moaddab; Mohammad Asgharzadeh; Bahareh Mehramouz; Sounkalo Dao; Hossein Samadi Kafil
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-16       Impact factor: 2.629

6.  Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study.

Authors:  Federico Antoniciello; Davide Roncarati; Annamaria Zannoni; Elena Chiti; Vincenzo Scarlato; Federica Chiappori
Journal:  Front Mol Biosci       Date:  2022-05-11

Review 7.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

8.  In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains.

Authors:  Jun-Won Chung; Su Young Kim; Hee Jung Park; Chang Su Chung; Hee Woo Lee; Sun Mi Lee; Inki Kim; Jhang Ho Pak; Gin Hyug Lee; Jin-Yong Jeong
Journal:  Gut Liver       Date:  2017-09-15       Impact factor: 4.519

9.  Capsule Design for Blue Light Therapy against Helicobacter pylori.

Authors:  Zhangyong Li; Binbin Ren; Haiyan Tan; Shengrong Liu; Wei Wang; Yu Pang; Jinzhao Lin; Chen Zeng
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

10.  Antimicrobial activity of silver nanoparticles encapsulated in poly-N-isopropylacrylamide-based polymeric nanoparticles.

Authors:  Muhammad Qasim; Nopphadol Udomluck; Jihyun Chang; Hansoo Park; Kyobum Kim
Journal:  Int J Nanomedicine       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.